Quenton Nelson out this Sunday, week-to-week with knee injury

Mike Macdonald stepped onto the Seahawks’ press podium on Friday and, without any flourish, announced that Quenton Nelson – Seattle’s recent acquisition from Indianapolis – would miss the Sunday showdown with Arizona. “Quenton is going to be out,” the head coach said, adding that the veteran left guard would undergo a “minor procedure” and be placed on a week‑to‑week list rather than the injured reserve.

What the Seahawks’ medical staff unearthed after the trade – a lingering knee issue that required re‑imaging and ultimately a cartilage‑clean‑out surgery – suggests the club knew the guard arrived with a problem. As the Seahawks’ official statement put it, “He had something he was dealing with when he got here…we’ve done the due diligence, and everybody agrees it’s best to take care of it now and play the long game.”

The procedure itself, described by multiple outlets as “minor,” is aimed at clearing loose cartilage that has been causing pain. ProFootballRumors points out that the surgery will remove loose fragments but not replace the cartilage, leaving the joint “bone on bone” in the long run. That distinction matters: while the operation may get Nelson back on the field sooner, it does not guarantee durability, especially for a lineman who consistently bears the brunt of defensive pressure.

Seattle’s roster depth will be tested. With starter Sam Darnold also out (quad) and several linemen on the injury list – left tackle Charles Cross (ankle), defensive tackle Leonard Williams (stinger), linebacker Uchenna Nwosu (ankle), and others – the Seahawks will rely on veteran Anthony Bradford to slide back into right guard, while Grey Zabel returns to left guard, a position he occupied early in his career. Coach Macdonald emphasized the team’s 70‑man roster philosophy, noting that “this is a strength of the Seahawks.” Yet the optics of a high‑profile trade yielding a player who can’t suit up for his debut raises questions about front‑office transparency and the valuation of draft capital in injury‑prone veterans.

The unresolved pieces linger. Moreover, the long‑term impact of operating on cartilage‑depleted knee tissue is still uncertain for a player who relies on lower‑body stability. What’s clear is that the Seahawks must now navigate a week of compromised line play while hoping their depth scheme holds, and the trade that once seemed a bold push for a playoff push now reads like a cautionary tale about medical diligence in the NFL’s high‑stakes market.